Ironshore Pharmaceuticals launches Jornay PM
Ironshore is introducing Jornay PM (methylphenidate HCl) extended-release capsules. The product is a central nervous system stimulant approved earlier by the Food and Drug Administration for the treatment of ADHD in patients 6 years and older.
Jornay PM is the first and only ADHD stimulant medication that is dosed in the evening and helps improve and control symptoms throughout the day, the company said.
The evening administration of a stimulant medication is made possible by Delexis, Ironshore’s novel drug delivery platform. Delexis contains two functional film coatings that act synergistically to achieve a unique pharmacokinetic profile. The first layer delays the initial release of drug for up to 10 hours while the second layer helps to control the rate of release of the active pharmaceutical ingredient throughout the day.
“The launch of our first commercial product for the treatment of ADHD marks an important milestone in the company’s history and demonstrates our commitment to developing innovative, patient-centric treatment options for patients with ADHD,” Ironshore Pharmaceuticals and Development CEO David Lickrish said. “We are delighted to offer the ADHD community a novel medicine, developed over a 10-year period and supported by nine clinical studies, including two pivotal trials, that works when patients wake up, but does not come at the expense of coverage throughout the day.”
Jornay PM is the first and only ADHD stimulant medication that is dosed in the evening and helps improve and control symptoms throughout the day, the company said.
The evening administration of a stimulant medication is made possible by Delexis, Ironshore’s novel drug delivery platform. Delexis contains two functional film coatings that act synergistically to achieve a unique pharmacokinetic profile. The first layer delays the initial release of drug for up to 10 hours while the second layer helps to control the rate of release of the active pharmaceutical ingredient throughout the day.
“The launch of our first commercial product for the treatment of ADHD marks an important milestone in the company’s history and demonstrates our commitment to developing innovative, patient-centric treatment options for patients with ADHD,” Ironshore Pharmaceuticals and Development CEO David Lickrish said. “We are delighted to offer the ADHD community a novel medicine, developed over a 10-year period and supported by nine clinical studies, including two pivotal trials, that works when patients wake up, but does not come at the expense of coverage throughout the day.”